Nadiya Chen

Nadiya Chen is a senior finance and communications executive with extensive experience across both Taiwan-listed and Nasdaq-listed companies in the TMT and healthcare sectors. Her expertise spans investor relations, corporate communications, ESG strategy, and capital-market engagement, bridging global investors with Taiwan’s fast-evolving innovation landscape.

As Head of IR, PR, and ESG at Bora Pharmaceuticals (TWSE: 6472), Nadiya leads capital-market strategy, disclosure, and stakeholder engagement post a period of significant M&A activities, global expansion, and organizational transformation. In an environment often marked by share-price volatility and shifting investor expectations, she focuses on reinforcing transparency across global stakeholders.

With a background that combines financial acumen and narrative clarity, Nadiya has been instrumental in translating complex transformation stories into credible, compelling messages that strengthen market understanding and trust. This approach reflects her broader IR experience, having consistently joined companies during periods of rapid change and growth, where she has helped elevate market cap from multiple dimensions.

Prior to joining Bora, she managed new business operations in Taiyuen Textile, and IR/PR of Lotus Pharm and Himax Technologies. Nadiya was nominated “Best IR By An Asia Pacific Company In The US Market” by IR magazine in 2015.